Clinical Trial Update: Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

View source ↗

Summary

A clinical trial is evaluating double immunosuppression with or without an anti-fibrotic therapy for systemic sclerosis-associated interstitial lung disease and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Snippet

Sponsor: University of Patras | Conditions: SSc-Systemic Sclerosis | Status: RECRUITING